The 10 Successful Magnetic Leaders Revamping The Healthcare

VOL 12 | ISSUE 01 | 2020

The 10 Most Successful

MAGNETIC

LEADERS

Revamping the

Healthcare 2020

NETWORKING

AND BUSINESS

A CONNECTED

WORLD

GROUND REALITY

THE IMPACTS OF

PANDEMIC IN PHARMA

AND BIOTECH

LABORATORY

CMIC.Inc

Leading Treasure in Healthcare Industry

Especially in Pharmaceutical Sector

Editor’s Desk

A Golden

Opportunity

to Win and Shine

he outbreak and the effect of Covid-19 took

Teveryone by surprise. This is a unique challenge.

We have to adapt to the “new normal” of working

remotely in our daily operations. It has forced us to

prioritize health and to focus on critical matters in both

business and life. The pandemic has its challenges and

opportunities. Although it has a lot of thought to it.

We have to see things from a positive angle and find new

opportunities in the current situation. Leaders are involved

in online leadership and scientific courses to refresh the

knowledge on the situation and connect with other

executives. Leadership styles have become contextual. A

great leader is someone who can recognize the awareness of

such a situation by interaction and adjust to the actual

reality. It is although empathy, fairness, positivity, and

leading by example that will build credibility and engage

people.

Leadership is not for everyone. If leaders decide to embark

on one such entrepreneurial venture, they should not expect

things to go according to the initial plan. They will always

face disbelievers. All you have to do is, trust your gut

feeling and channelize criticism as a motivation & driving

force, and celebrate every little win. A leader is defined as a

risk-taker. The Leader will know when it is time to abort or

cash-in, any business model. Every leader should be able to

listen, respect all points of view, make decisions for all, and

not be afraid to make those decisions. Just believe in what

you do! Stay motivated, persistent, and never give up.

Ultimately, it is important to remember that not trying is

worse than failing!

The world of healthcare has changed exceptionally

over the last few months. Today, paramedical and

pharmaceutical leaders have become the focus of

healthcare where the aim is patient-centric. With an

intent to acknowledge and admire these passionate

leaders in healthcare, CIO Look has enlisted “The 10

Most Successful Magnetic Leaders Revamping the

Healthcare 2020” - Jenny Lin is one such healthcare

leader, COO & Board Member at CMIC, Inc. She

holds 26 years of executive/lab management

experience in bioanalytical and analytical laboratory

operations in support of drug discovery, pre-clinical,

and clinical drug development. Moreover, she is

proficient in GLP, GMP, GCP, OECD, ICH, and 21

CFR part 11 regulations and business strategic

planning & execution.

Let’s unveil more alike and motivating stories of such

healthcare leaders in this special edition and spread the

word about their contribution in making this world a

better place. These leaders with their healthcareeducational

skills, business competencies, and

technical know-how, are taking healthcare to the next

level.

Rohit Chaturvedi

Finally, while flipping the pages, don’t forget to go

through the articles and CXOs written by our in-house

editorial team and industry experts respectively.

Let’s begin...!

08

Cover Story

CMIC Inc.

Leading Treasure in Healthcare

Industry Especially in

Pharmaceutical Sector

22

Tech Insight

Haseeb Awan

38

Ground Reality

The Impacts of

Pandemic in Pharma

and Biotech Laboratory

Article

26

Networking

and Business

A Connected World

Contents

Elaine M. Wallace

Elevating Standards

of Education in

Healthcare

14

18

Elias Chabtini

Becoming a

Trendsetter in

Cosmetic Industry

Karim Smaira

Committed to the

Rare Disease

Community

30

Katrin Keller

34

A Leading Name

in the Health-Tech

Space

METRENDALYTICS

Combining Knowledge

and Technology to Bring

Efficiency in Business

42

Triox Nano

48

Pioneers in point

of care programmable

medicine! presenting

the next healthcare

revolution!

Editor-in-Chief

Sumita Sarkar

Managing Editor

Anish Miller

Executive Editor

Rohit Chaturvedi

Assistant Editors

Jenny Fernandes

Visualizer

David King

Art & Design Director

Asha Bange

Associate Designer

Sanket Zirpe

Co-designer

Kushagra Gupta

Senior Sales Manager

Kshitij S

Business Development Manager

Peter Collins

Marketing Manager

John Matthew

Sales Executives

David, Martin, Maneesh

Technical Head

Jacob Smile

Business Development Executives

Steve, Joe, Aidan, Prathamesh

Technical Specialist

Aditya

Digital Marketing Manager

Marry D'Souza

SME-SMO Executive

Amol Wadekar

Research Analyst

Frank Adams

Circulation Manager

Database Management Technology Consultant

Robert Brown Stella Andrew David Stokes

sales@insightssuccess.com

December, 2020

Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess

We are also available on :

Copyright © 2020 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any

form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success.

Reprint rights remain solely with Insights Success.

Company Name

CMIC, Inc

cmicgroup.com

Management

Jenny Lin

Chief Operating

Officer/Board Director

Brief

CMIC, Inc. was established as a strategic cornerstone for

CMIC Group’s North America growth. It has the vision to

provide a solution service as “Pharmaceutical Value Creator”

(PVC) that encompasses an entire value-chain of

pharmaceutical companies.

GENPHARM

genpharmservices.com

Karim Smaira

Founder and CEO

Genpharm is managed by senior pharma executives with vast

regional experience having held senior management roles in

multinational pharmaceutical organizations.

Medica Trading LLC

medicagroup.com

Metrendalytics

metrendalytics.com

Nova Southeastern

University

nova.edu

Elias Chabtini

CEO

Jan Miotto

President

Elaine Wallace

Dean Professor

Medica Trading LLC is a leading Dubai-based medical trading

company, committed to providing aesthetics, dermatology, and

dental machines and products in the UAE and operating

countries which meet the expectations of the interested parties.

Metrendalytics was founded by scientists, for scientists. The

goal is to provide integrated solutions which provide a

consolidated view of all of one’s operational data—whatever

the source on one shared platform for faster interactive

collaboration and client service with reduced risk.

Elaine M. Wallace, an Osteopathic Physician, certified in

Family Medicine, Sports Medicine and Neuromusculoskeletal

Medicine.

samedi GmbH

samedi.de

Katrin Keller

Manager

Samedi GmbH founded in 2008 with the goal to solving

communication problems beyond the boundaries of the

individual medical practice wall and clinic wall for the benefit

of the patient.

TrioxNano

trioxnano.com

Roy Farfara

MD Founder & CTO

TrioxNano’s revolutionary technology, termed S.M.A.R.T, an

acronym for Stimuli Multi Adjusted Responsive Technology, or

simply put “Programmable medicine” is based on combinations

of DNA coding, DNA molecular machines and mesoporous

nanoparticles.

Cover Story

Leading Treasure in Healthcare Industry

Especially in Pharmaceutical Sector

Our vision is to advance the innovation

of products and solutions that will

empower people worldwide to achieve

greater health and well-being.

Jenny Lin

Chief Operating Officer

& Board Member

CMIC, Inc.

‘‘

Our goal is to be your top tier

Bioanalysis solution

provider for drug discovery,

development through

commercialization.

Pharmaceutical sector is blooming at

subsequently than ever being imagined.

And only few companies proved

themselves worthy of it. Meet CMIC, Inc., a

leading CRO (Contract Research Organization)

and a provider specialized in bioanalytical

services, whose cutting-edge capabilities and

sophisticated expertise in various aspects helped it

achieve a greater stature in the business. Its

bioanalytical services are in support of TK/PK/PD

Biomarker studies for pre-clinical and clinical

developments. It firmly focuses and holds

expertise in bioanalytical method development,

method validation/qualification and study sample

analysis for small, large molecules and

Oligonucleotide. The “CMIC” name originally

stood for “Current Medical Information Center”,

and the company remains committed to the

advancement of medicines and healthcare

revolution. As a strategic drug development

partner, CMIC helps sponsors to overcome

challenges in bioanalysis with expertise, rapid data

turn-around-time, and high-quality customer

services.

The company states its core values intercepted

through, W & 3C;

• WELLBEING: Fully Live Every Moment

• Challenge: Liberate opportunity by changing

our vantage point

• Change: Transform without seeking refuge in

conventional wisdom

• Communication: Proactively reach out to

people and society

The Story behind CMIC

CMIC Inc., CMIC’s Chicago, Illinois location is a

global CRO with over 30 years’ experience, the

laboratory offers bioanalysis for non-clinical and

clinical projects, both GLP and non-GLP within a

state-of-the-art facility that has the capacity to

accommodate quick turnaround for high-volume

projects. CMIC’s skilled researchers provide deep

expertise in small and large molecule bioanalysis,

biomarker services and oligonucleotide bioanalysis

expertise. Purpose built in 2010, CMIC Inc.’s

contract bioanalytical and biomarker laboratory is

located nearby Chicago O’Hare International

Airport and is one of four global contract

laboratories in the CMIC Holdings group.

Current large molecule capabilities include

detection of oligo, peptide, or antibody

therapeutics using standard ELISA or MSD-ECL

ligand-binding platforms. A variety of formats are

The 10 Successful Magnetic Leaders Revamping the Healthcare, 2020

available including but not limited to direct, indirect,

sandwich, competitive, and multiplex which can be

performed with off-the-shelf assays or developed in-house.

For oligonucleotide detection by hybridization, CMIC Inc.

brings a wealth of experience with capture and detection

probe-based assays for quantitation of antisense or siRNA

based therapies.

CMIC Inc.’s flow cytometer has the ability to detect up to

13 colors, and is equipped with a 96-well plate loader to

handle high-throughput applications. The software is 21

CFR Part 11 compliant, and displays easily viewed data.

Immuno-phenotyping on whole blood, PBMC, or bone

marrow can be performed with a general panel to determine

the percentage of T- and B-cells, Natural Killer, and

monocyte/macrophage lineage within the leukocyte

population. Alternatively, specialized panels such as

regulatory T-cells (Treg cells) can be characterized. Treg

cells play a role in regulating or suppressing other cells in

the immune system, and can be defined by the cellular

markers CD25, FoxP3, and CTLA4, and the intracellular

cytokines IL4 and TGFβ. Another specialized type of T-

cell (one that is important for battling foreign invaders) is

the CD4+ memory T-cell, which can be identified by

staining CD45RA and CCR7 to determine the percentage of

naïve, central memory, and effector memory T-cells within

the overall T-cell population. Other flow cytometry

applications include confirmation of gene expression in

order to establish potency of gene therapy, or the efficacy of

a treatment regimen.

Real-time qPCR has emerged as a powerful tool for

bioanalysis, and offers the ability to explore mRNA gene

expression. RNA can be isolated from whole blood,

PBMC, bone marrow, solid tissue, or matrices such as

urine, saliva, or cerebrospinal fluid and then added to a

reverse-transcriptase quantitative PCR to accurately

quantify mRNA levels. Alternatively, DNA can be isolated

and added to a qPCR to identify single nucleotide

polymorphisms, for detection of known mutations, or to

determine individual copy number variation. One of the

more powerful applications of qPCR is the ability to

multiplex, which is the detection of many targets within the

same reaction. This can be leveraged for biomarker

screening to determine which genes are differentially

regulated in response to therapeutic treatment. CMIC Inc.’s

qPCR instruments are compatible with a variety of

flourophores and are fully supported by the vendor,

providing for seamless design of specialized panels, thereby

saving precious time and cost. Yet another application for

qPCR is detection of viral nucleic acids in order to

determine the remaining levels of a vaccine or gene therapy

vector in order to establish washout and allow further

optimization of a dosing regimen.

CMIC Inc. plans to add droplet digital PCR and cell-based

assays in 2021 to augment current GLP capabilities for

bioanalytical support of gene therapy programs. While

industry and regulatory contemporaries are building out a

knowledge base for new and updated assays, CMIC Inc.

will be well positioned to support large molecule biologics

ranging from monoclonal antibodies, biosimilars, anticancer

compounds, peptide-based therapies, gene therapy,

and vaccines.

A Glimpse into Jenny’s Life

Jenny Lin, Chief Operating Officer and Board Member.

She holds 26 years of executive/lab management

experience in bio-analytical and analytical laboratory

operations in support of drug discovery, pre-clinical and

clinical drug development. Moreover, she is proficient in

GLP, GMP, GCP, OECD, ICH and 21 CFR part 11

regulations and in business strategic planning and

execution. Her expertise includes building organizational

quality system, staff training, bioanalytical/analytical

method development/validation, bioanalytical sample

analysis, analytical development for CMC submission,

chromatography purification, stability studies, reference

standard certification, QC support for GMP manufacture.

She has been also a selected member for Global Bioanalysis

Consortium (GBC) making recommendations for global

Bioanalysis harmonization. She serves as editorial board

member for peer reviewed journal and chair for

international conferences.

Besides, she is an author and co-author for approximately

40 publications, white papers and presentations and is the

inventor of 7 issued US patents. Jenny earned her BS in

Analytical Chemistry at Peking University and her MS in

Medicinal Chemistry at University of Connecticut. She is a

member of the American Society of Mass Spectrometry

(ASMS), American Association of Pharmaceutical

Scientists (AAPS), American Chemical Society (ACS),

National Association of Professional Woman (NAPW) and

Global CRO Council (GCC).

Future of CMIC

CMIC CREED as corporate philosophy, consists of

Wellbeing, Challenge, Change and Communication

(W&3Cs). The company has been applying these

philosophy to continuously evolve itself in line with market

changes, and will do so in the future. Moreover, by further

expanding from the current “Pharmaceutical Value Creator”

(PVC) business model, the company has an aspiration to

become a “Personal Healthcare Value Creator” (PHVC) to

contribute for and to address to the up-coming personalized

medicine and individual patient quality of life.

Top 10 Successful Magnetic Leaders Revamping the Healthcare -2020

Elaine M. Wallace

Elevating Standards of Education in Healthcare

The world of healthcare has changed remarkably

over the last few years. Today, the patient has

become the focus of the healthcare where the

solutions are becoming patient-centric. In its upcoming

edition “Top 10 Successful Magnetic Leaders

Revamping the Healthcare” Insights Success is praising

those leaders who are making remarkable progress in the

sector with their advanced solutions and efficient

services. One such healthcare leader is Elaine M.

Wallace, an Osteopathic Physician, certified in Family

Medicine, Sports Medicine and Neuromusculoskeletal

Medicine.

About Elaine

Elaine began her career in private practice in Kansas

City Missouri, where her practice was a true family

practice; she did her own D&C’s and tonsillectomies;

she delivered one to two babies per week; she took care

of geriatric and pediatric patients; established and was

the director of a rape crisis center at Lakeside Hospital in

Kansas City Mo. She loved family medicine, but during

the mid-80’s, she made a transition to the Kansas City

College of Osteopathic Medicine where she became the

Chair of the Department of Osteopathic Principles and

Practice. Shortly thereafter (1990), Elaine became the

Assistant Dean of Clinical Education and has spent the

remainder of her career in Medical Education.

According to Elaine, Physicians are often not educators,

so with her new role as a dean she went back to school at

University of Kansas and received a degree in Higher

Education Leadership and Administration. This has been

followed by two other master’s degrees in education

from NSU, one in Brain Based Learning as well as one

in Curriculum Development. She also has a master’s

degree in criminal justice with attention to forensic

psychology and is currently in NSU Law School in the

Education Law program.

A Proficient Educator

One of the most wonderful things about Elaine’s job is

that she oversees 6 Bachelors programs, 6 masters

programs, two PhD programs and a professional

program in Osteopathic Medicine – the largest medical

school within the state of Florida. Four of the bachelor’s

programs are “track programs” into the DO medicine

program. This means that the students take their

bachelor’s training at NSU and are offered interviews

with the DO program upon successful completion. This

has allowed the college to admit a diversity of applicants

from non-traditional fields including Public Health,

Health and Wellness Coaching, Nutrition, and soon,

Biomedical Informatics. This allows changes the

composition of a typical medical school class and fosters

a depth within the class that many other medical schools

do not enjoy.

Current Challenges and Effects

“COVID 19 offers challenges and opportunities,” says

Elaine. She further adds, the biggest challenge has been

the interruption of the third- and fourth-year clinical

rotations at affiliated hospitals, which are not able to

accommodate the students due to being overwhelmed

with COVID 19 patients. This has caused the college to

look with greater depth into online training and

simulation training. Many of these materials were

foreign, but they do offer education in a new modality

that many of the students relate to.

Learning through Reading, Travelling and

Understanding People

Elaine is an avid reader. She read one book per week.

She asserts “I have read every novel written by Joyce

Carol Oates. Having followed her career through her life

and my life, I have grown to see the nuances in people,

14 | DECEMBER 2020 www.insightssuccess.com

Elaine M. Wallace,

Assistant Dean of

Clinical Education

www.insightssuccess.com DECEMBER 2020 | 15

the absurdities of life and understandings of the

vicissitudes of society.” Travelling world is also

important to Elaine. She has been in 110 countries and

on all 7 continents. She has also studied the great

religions of the world in their origin countries and has

learned that people the world over, are much the same –

wanting what is best for their families and in their lives.

Advising From Experience

Elaine opines “Every leader should be able to listen; to

respect all points of view; should demonstrate kindness;

should make decisions for all; should not be afraid to

make those decisions; should have a great sense of

humor and should not take themselves too seriously.”

On advising upcoming leaders, Elaine says “I would

recommend listening in the quiet and finding the

resonance of your passion and your mission. Then,

never sway from that.”

“Find your passion; identify your

mission; keep your eye on your

end goal; be sure you can sleep

with yourself with a clear

conscious every night; and laugh

heartily every day.”

Combining Leadership and Team Work

Elaine believes, she is supported by wonderful teams of

people. She governs, not in a top down management, but

with two management teams, one that is administrative

with 5 members and one that is academic with 7

members. The team discusses all issues together; with

multiple people having the “30 thousand-foot view” we

are able to critique one another, guide one another and

help one another from our diverse experiences. She also

is guided by a vision of “how we get things done”, not

“can I get things done”. Elaine is not afraid, if the front

door is closed, to go through the back door or through

the window to get to where she needs to go. She also

laughs a lot. This is the key to much in life.

A Leader also A Mother

Elaine maintains a balance of personal and professional

due to the fact that she is raising three young children:

twin 8-year-old boys and a 12-year-old daughter. They

keep one’s sense of reality and reminds me every day of

the value of love and kindness over all else. She says “I

have also lived my life and my career knowing that my

values come first and at any given moment, I could walk

away and still be a happy person.”





Haseeb Awan

he days are long gone where the security threat

Tsurrounded our computer only. Modern problems

have expanded to our personal devices. The broad

classification of these threats would fall into four

categories:

1. Application-based threats;

2. Web-based threats;

3. Physical threats;

4. Network-based threats

Application-based threats: Privacy, information security,

and data security are inseparable, dependent on each other,

as well as, complimentary.

Web-application threats occur when the application

resembles an authentic application, but it is a disguise and

has the ability to skim your precious information.

The prime examples include malware and spyware where

your personal information is at stake.

Web-based threats: As subtle in nature, these web-based

threats remain unnoticed because visitors visit malicious

websites that are better from their front-end but in reality,

they are skimming your information by downloading

malicious content on your device.

Physical threats: This occurs when you lose your mobile

phone or if it has been stolen. This is a strong case for

hackers to loop into your personal information via your

device (as they have direct access to the hardware where all

your personal information is resting).

Network-based threats: This is where cybercriminals are

actively looking to encrypt your data with the use of public

Wi-Fi networks.

The advanced mobile threats comprises of:

a. Phishing attacks;

b. Data leakage;

c. Unsecure Wi-Fi (particularly public Wi-Fi) connection;

d. Sim Swap

Phishing attacks: A phishing attack is an online theft attack

that gains your personal information such as username,

password, and even your financial information. Phishing

education is mandatory to mitigate the risk of this threat to

an acceptable level. It is incumbent to learn that phishing is

different from conventional scams. The thwarting ways

would differ depending on the level of fraud committed and

who is the victim (corporation or individuals).


Tech Insight

Haseeb Awan


For corporations it would be:

1. Design policies in place and the communication should

be strong,

2. There should be a control designed to ensure the

legitimacy of an email and it should be communicated to

loyal customers (as well as others),

3. Scan the internet for likely phishing sites,

4. Implement a quality anti-virus, anti-spam, and content

filtering at the gateway.

For individuals it is simple:

1. Block malicious or fraudulent email promptly,

2. Detect and delete malicious software immediately,

3. Block the sensitive information delivery to third parties

automatically,

4. Apply skepticism wherever necessary.

Data Leakage: Data leakage occurs where there is a

compromise in the (information) confidentiality breach.

This refers to an unauthorized leakage or possible data

transmission within an organization to a third party. The lost

data is either private, sensitive, or confidential in nature.

The data could be lost due to a system crash or even a

deliberate deletion.

Ÿ

Safeguards-

Sim Swap: A fraudster beautifully impersonates you and

manages to get victims Sim deactivated. There is a

replacement activation without the knowledge of the victim

(Marimuthu, V., 2019).

This is a surplus for hackers where they can reset victims'

online accounts. EFANI was designed to mitigate such

happenings with a 100% money-back guarantee for 60-

days.

Ÿ Safeguards –

1. Beware of phishing - as it penetrates sim swapping

incidents. These sketchy emails and bogus logins can get

the hacker the required information and these key data can

spawn a sim swap occurrence.

2. People should rely less on online space, they should

reduce the personal information to be stored online. Social

engineering is an initial sim swapping stage, where the

hacker collects as much information as they want. Keep

compromising information low-key such as your digits,

date of birth, mailing address off your account.

3. Protect your accounts or crypto space using Yubikey,

frequently changing the PIN, multi-factor authentication.

Please do not trust SMS-based 2FA.

1. Quarantine your outgoing information (which is private,

sensitive, or either confidential in nature) from your

organization network.

2. Archive suspicious files.

3. Quarantine sensitive files to be copied into USB or

smartphones.

4. Block print jobs that contain private information.

5. Discover confidential information that is stored on

databases, organizational laptops, and workstations.

Unsecured Public Wi-Fi: Public Wi-Fi networks offer

potential privacy risks and invite security issues. People are

tempted to pursue public WiFi which is controlled by a

hacker. It invigorates the MITM attack.

Ÿ Safeguards –

1. The network should be verified. Hackers are smart but

users are smarter, it is better to play smart.

2. Using a VPN (Virtual Private Network) which is the most

secure surfing option on public networks.

3. Use Antivirus and keep the Firewall Enabled.



A

Connected

World


Networking and Business


rom speedy access to the

Finternet to the ability to

instantly get in touch with

almost anyone anywhere in the world

by dialling just a few digits, the

contemporary technology-oriented

world has changed the way we connect

and communicate. With smart devices,

people have also become smarter.

Though the processes of connecting

have become simpler, there is a need

for effective communication and

service between users, applications,

services, devices and so forth. This is

where network infrastructure comes

into the picture.

Let’s consider the current situation.

COVID-19 has compelled IT businesses

to close their workplace and

made their employees work remotely.

As employees working from a different

location on enterprise networks

consists of traffic and thus, centralizing

traffic could have been a challenge for

business. To address this challenge,

there arises a need for a suitable

network infrastructure.

Along with the employee's performance

and excellent equipment, the

agility and productivity of organizations

also depend on the robust and

secured network infrastructure. In

today’s digital age, businesses cannot

afford to have poor user experience and

security issues that can impact

employee productivity and thus, are

realizing the importance of adopting

comprehensive network infrastructure.

With sound networking solutions,

businesses can ensure optimum

efficiency and excellence in their

operations.

Even though enterprises have understood

the importance of network

infrastructure, choosing the right

networking services partner is another

challenge. Businesses are in search of

partners with integrated networking

solutions and a team that possesses the

required skill-set and industry rich

expertise. They are on the lookout for a

solution provider which they can trust

and rely on.

Taking this need into consideration,

many networking solution providers

have come forward with cutting edge

solutions and are ensuring the smooth

running of the enterprises without any

performance issue. The changes start

with migration to 5G technology. It is

built to increase the network speed and

reduce latency. It will assist in the

mobilization of employees allowing

them to work from any part of the

world.

Next up is harnessing the prowess of

Artificial Intelligence(AI) and Machine

Learning(ML) in solving business

problems in real-time. Right from

hiring the most suitable candidate to

process transformation and enriching

customer experience, AI and ML can

deliver solutions to help business

flourish.

Cloud Solutions are seen as the way

forward to maintain business continuity

and resilience and are being proven

effective in today’s crisis. It has helped

teams stay connected over work and

seamlessly deliver services proving

that physical distances can’t dampen

the innovative spirits. Digital experiences

supported by Cloud have found

new takers during the pandemic and

the technology is poised for steady

growth.

With so much dependence on networks,

it is bound to grow complex. To

reduce and manage its complexity and

shift creation of network rules and its

maintenance, Intent-based networking

is one solution to look-out for. The idea

is to put a network controller(deploying

AI/ML) that can

regularly monitor the network, suggest

best paths and continuously adjust the

network performance for maximum

output.

And while we are at it, how can we not

mention Internet of Things(IoT). From

empowering manufacturing, providing

enhanced tracking to logistics, to

helping the healthcare sector in remote

monitoring and more, IoT is redefining

the way industries work and behave.

As connectivity grows, so does IoT’s

application.

Networking is evolving and with each

new step that it takes, it presents a new

opportunity for businesses to digitally

transform and scale their services.


Top 10 Successful Magnetic Leaders Revamping the Healthcare -2020

“ We strongly feel that we have a responsibility towards rare and genetic disease patients and

their families in the Middle East region,” says Karim Smaira. He is the Co-founder and

CEO of Genpharm and has worked in several geographies and served in different sales,

marketing and management functions. Karim’s entire career has been focused on international

operations and emerging markets. He left the corporate world and co-founded Genpharm in 2012. Since

then he has been serving as its CEO.

In an interview with Insights Success, Karim shares his experiences, challenges, and advises emerging

business leaders to become more resilient, motivated and focused.

Below are the highlights of the interview:

How do you diversify your organization’s healthcare offerings to entice the target audience?

We are a very focused organization with a clear vision and an aspirational purpose. We strongly feel that

we have a responsibility towards rare and genetic disease patients and their families in the Middle East

region. Access to Orphan drugs has always been complicated due to lack of overall awareness for many

of these diseases, diagnostic challenges and reimbursement issues due to the high costs of drugs in this

sector. We have built our vision on tackling these challenges through “Bringing Cures to MENA

Patients”. We diversify our offering by trying to overcome them by bringing breakthrough treatments

and innovative solutions to as many of these rare diseases as we can. We always try to walk the talk and

we are currently the first and only company that has launched gene therapy treatments in the region.

As a director and business leader, describe the challenges you are having during the pandemic

COVID-19 and what initiatives are you taking to mitigate them.

The proportion of the outbreak and the impact of Covid-19 took everyone by surprise. This is a unique

challenge. We had to adjust quickly to integrate the “new normal” of working remotely into our daily

operations. Like for many, it accelerated our adoption of digitalization. We have for example conducted

Karim Smaira

Karim Smaira

Committed to the Rare Disease Community



actions, are learnt during these early

years. Your life experiences just add onto

these building blocks. I have lived in 5

different countries, learning languages

and adopting cultures along the way. This

has been one of the most determining

factors for me and has taught me the

ability to work and communicate

globally.

I am a passionate reader of geopolitics,

history, biographies, management and

leadership books. My inspiration has

come as much from visionary business

leaders, philanthropists, professional

athletes and ordinary people that have

taken inspiring initiatives. It would be

extremely difficult and unjust to list a

couple of book titles or names.

As a keynote business leader, what are

some of the vital attributes that every

leader should possess?

many webinars and on-line CME conferences, reaching in fact significantly

more physicians than we would have in a physical conference, and we will

continue to do so.

We are a regional organisation with staff in many geographies. Our agility and

lean structure allowed us to adapt swiftly, to be in sync with measures taken by

different governments. We also introduced safety measures to ensure the safety

of our employees working in the office. Like with every crisis, regular

communication to and with employees in both a group and/or in individual

setting is critical and we have on many occasions as we can reassured and

engaged with them. We are very proud to be one of the few companies that

have neither reduced salaries nor let go employees; in fact we have hired 3

additional colleagues during this crisis.

What people, what books, what life factors have influenced and impacted

you?

I have been fortunate enough to cross paths with many inspiring people and

leaders throughout the years. Nevertheless, I believe the childhood years and

the civic values embedded during your upbringing, tend to guide you

throughout your life. At the risk of sounding cliché, I am convinced that traits

like honesty, respect, compassion, standing for your principles and owning your

Leadership and leadership styles are

really contextual. A great leader is

someone who can recognise the

specificity of each situation or interaction

and adjust to the actual context. I do

believe though that empathy, fairness,

positivity and leading by example are

attributes that build credibility and

engages people.

How do you maintain balance between

your professional & personal life?

As an entrepreneur this balance is mostly

fictional, particularly in the first 3 years

of the venture. As the business is proven

sustainable as well as successful and trust

is built with employees that balance

becomes attainable. I have now become

better at making time for a family trip,

exercising regularly and satisfying some

hobbies and recently earning a boating

license.

How do you sustain your creative

leadership spirit in this crucial time?


“You never have

to apologise

for doing the

right thing.”

The current crisis has brought a lot of reflection. It forced

me to do a prioritization exercise and to focus on critical

matters in both business and life. I have enrolled in a couple

of online leadership and scientific courses to refresh some

of the knowledge and connect with other executives.

My priority is to continue expanding and growing the

business both geographically and organically. We have

established ourselves as the rare disease and gene therapy

experts. We need to leverage and build on this to make sure

that patients in the Middle East are not left out of the

scientific and therapeutic benefits provided by these

innovations. We expect several breakthroughs in the near

future and we want to be positioned as the natural partner in

the region.

What advice would you like to give to the emerging

business leaders/entrepreneurs?

Entrepreneurship is not for everyone. If you decide to

embark on an entrepreneurial venture don’t expect things to

go according to your initial plan. You will always have

doubters. More people will be cheering for you to fail than

to succeed. Stick to your gut feeling and use criticism as a

motivation and a driving force. Make sure you celebrate

every little win! Nevertheless, know when it is time to pull

the plug on your idea or business model. An entrepreneur is

by definition a risk-taker. It is important to remember that

not trying is worse than failing!

What are your future endeavours/objectives and where

do you see yourself in the near future?






Ground Reality

The Impacts of Pandemic

in Pharma and Biotech

Laboratory

The Coronavirus disease 2019 (COVID-19) was

and is a world-changing event that has touched

the lives of everyone on the planet, but on a

positive note, it was an accelerant of technology and has

forced companies to innovate. Companies that can do it

better, faster, cheaper, more efficient, and have more

creative approaches to problem solving will leapfrog to

the forefront of the industry. We will see more of a focus

to develop and implement technology that can deliver

transparent, secure, and reliable data sharing remotely.

When COVID-19 was declared a pandemic, the industry

rapidly responded with efforts put into place to

effectively protect patient safety in their trials. Across

the world, clinical trials answering important healthcare

questions were stopped, or temporarily paused to

possibly restart later, some with important modifications.

Pharmaceutical companies and clinical research

organizations greatly felt the effects of the COVID-19

outbreak on the clinical trial life cycle and began to

incorporate remote ways of working to mitigate

disruption. Over the last decade, regulators have been

advocating for greater use of technology, virtual trials,

and SMART trial designs. In the era of COVID-19,

ongoing studies were now faced with new challenges

like site closures, quarantines and limited access to study

documents. As a result, clinical study teams are now

relying heavily on remote monitoring and a more secure

means of document sharing in order to meet clinical

study timelines.

As a laboratory solution developer for the Pharma and

Biotech industry, it's important to highlight this

background as an important framework which provides a

basis for the direct impact of the COVID-19 era on the

bioanalytical business today as well as providing insight

of what the lab of the future needs to become. For

example, direct impact for the laboratory when pharma

companies moving toward more efficient SMART

clinical trial adaptive designs, which allows for the

continual modification of the trial based on interim data,

is that in in addition to help in shortening development

time, such designs may reduce the total sample size

needed thereby reducing the number of samples that

would need to be analyzed by the laboratory. So, in a

business very much driven by the number of samples to

be analyzed, when trials are delayed or producing much

less samples, labs have to pivot more towards a focus on

other activities such as the emerging market for

biomarkers in order to fill the void from lost sample

count to analysis types that would generate the same

revenue.

In addition to evaluating different business strategies,

labs need to be able to have access to information

technology to be able to manage operations more

efficiently including managing all processes remotely. In

order to be effective, everyone needs to be well versed

and comfortable using this technology. Use of

disconnected spreadsheets or non-database sources are


no longer a viable option

because they are

problematic for real time

sharing of information.

Despite the significant

investment that pharma has

made in technology, the #1

problem still facing the

scientist today is “Finding

data when I need it”.

Historically, technology has

focused on just replacing the

existing paper process with

electronic counterpart. We

must ask ourselves, are we

going to continue to build tools to

support existing business models and

existing ways of working or should we

begin to think about tools to reinvent the way

we do business?

Labs have now learned that they can and must work

remotely for many tasks without significant impact on

performance. Roles relating to project management

particularly fit this new paradigm very well but only if

the tools to do so are in place and folks are comfortable

with using them. The upside is improved quality of life

for staff who can significantly reduce commute time,

stress and costs. Time gained can be re-invested into

actual work for clients and conducting more science. For

the laboratory operations staff who are typically required

to be on-site as “essential” lab personnel, in addition to

adhering to typical lab safety requirements, new

pandemic related items such as spatial distancing, masks

etc have been included. Lab space available was the key

driver to ensure this was achieved. But what we have

learned is labs can actually reallocate space previously

used by project management and other remote staff and

even reduce their fixed costs on building office space etc

needed by giving folks who can work remotely the tools

and training to do so. Acting on both these learnings will

only become more important depending on how long this

pandemic lasts, and also as proactive preparedness for

the next one. Perhaps we should already be building for

this next phase? If non-essential folks can mostly work

from home, how can we reduce the need for “essential”

lab staff to work on site? Is the lab of the future one

which places much less burden on needing so many

scientists to be on site and instead leverages integrated

operational robotics, machine learning and remote

control of these laboratory systems?

Tools that enable a flexible business model, are cost

effective, and allow for remote access will be in high

demand moving forward and will allow us to get beyond

just managing data more efficiently. This allows us the

opportunity to start doing interesting things with that

data. Technologies that facilitated the ability to do this

have been brought to the forefront in lieu of the more

typical investments of continually just adding more

people and more instruments.

As virtual and remote working prove to be sustainable

methods of laboratory operations, it is unlikely early

adopters will revert back to the more laborious and timeconsuming

methods involved in the previous, highcontact

model. Consequently, companies will require

comprehensive platforms that address their changing

unmet needs and evolve their expectations of what an

integrated ecosystem can provide. Having a good

understanding of how much work is taking place

digitally will accelerate the technology enabled remote

work. At Metrendalytics, we have always recognized the

value of online work situation and had the infrastructure

in place to do so, therefore our operations did not skip a

beat during these pandemic times.

While the new normal is still unfolding, it is becoming

increasing clear that the future will be anything but

normal. We will begin to see more decentralization,

technology, and the need to make important decisions

not at the office. It is always important to remember

that during these times of disruption, uncertainty and

challenge, those who can reinvent themselves and move

forward will open a gateway to an abundance of

opportunities.


‘‘

Jan

Pharmaceutical services

consulting and software

development company,

focused on helping both

Miotto

President

Metrendalytics

pharma and CRO's

centralize operational

data for real-time use.



METRENDALYTICS

Combining Knowledge and Technology to Bring Efficiency in Business

etrendalytics was founded by scientists, for

Mscientists. Our goal is to provide integrated

solutions which provide a consolidated view of

all of one's operational data—whatever the source—on one

shared platform for faster interactive collaboration and

client service with reduced risk.

Metrendalytics recognizes that companies need a platform

to create comprehensive efficiencies across project planning

and execution with built-in analytic tools that are easy to

implement, are highly customizable, and cost-effective. To

enable this transformation journey to optimize “running the

laboratory business” with technology requires innovative

business solutions uniquely designed and customized

around a company's specific business model and processes.

Metrendalytics works to understand and build systems to

meet the unique process needs of each company. Then we

enhance the resultant process efficiency with corresponding

operational dashboard views with automated data

integration, aggregation, and signal detection in interactive

visualizations, which allows for centralized views and

remote monitoring of project performance in real-time.

Reviewers are able to zero in on signals and trends that

could affect operational performance and make smarter

decisions sooner about how to deploy resources. This

eliminates error prone, redundant entry and information

update lag time associated with typical business

management via various spreadsheets used for tracking of

these activities which are a basis of vast inefficiencies. As a

result, companies are essentially road blocked in the ability

to unleash the power buried in their operational data.

Metrendalytics' solutions have been presented at multiple

pharma/biotech meetings and conferences over the years.

Many of these presentations were from its customers. Most

recently, it was featured in a Bioanalysis Zone article on

how Metrendalytics' remote access solutions helped

businesses continue and thrive through the Covid-19

pandemic.

Extensive Service Offerings

Metrendalytics is a Pharmaceutical consulting services and

software development company focused on helping

pharma/biotech clinical operations and CRO's laboratory

operations centralize operational data for real-time use. The

company utilizes cloud-based, scalable, modular, rapid

development, and low-cost platforms which are analytics

and visualization enabled. The key to success is its software

combines existing internal and external data into a single

platform allowing customers to gain efficiencies and make

faster, more informed decisions. As a result, the firm helps

transition a business from a process that is reactive to one

that is more proactive.

The laboratory tools and technologies in the bioanalytical

laboratory have evolved and changed. However, leveraging

real-time business data to make more informed decisions

has seen limited progress. Further, additional time is

required to manually create plots and metric reports to be

used for analytics and process improvement initiatives. As a

result, less time is available for analyzing data to improve

business outcomes, customer service, and risk reduction.

Metrendalytics' software integrates the information from

existing software like Salesforce, Watson, NetSuite, etc and

incorporates these into a suite of applications to centralize

from proposal creation, award, and management of

milestones and deliverables through QC, QA, and reporting.

This provides a “one-stop-shop” for all critical business

functions and data so that each stakeholder has what they

need to efficiently complete their part. This means

laboratory and management personnel can spend more time

doing science and serving customers instead of chasing data

and re-entering information.

Passion and Expertise

Jan Miotto, President of Metrendalytics, had a successful

career in the drug development industry because of her

ethics of hard work and wanting to make things better for

the industry. This, along with a lifelong passion to learn and

apply new technologies is what drives the success of

Metrendalytics. She has assembled a group of like-minded

successful individuals who work together with the goal of

making customers successful.


Jan focuses on being authentic and bringing

value every day and trying her best not to

keep a fixed mindset in order to be able to

explore new opportunities. Jan says, “If you

wait for things to be perfect, you can miss

opportunities.” She brings a mindset to

never stop adapting. For Metrendalytics,

experimentation has helped them reach a

product-market fit.

Driving Improvement by Knowing Your

Customer

Metrendalytics' culture is to really partner

with its clients to help take them to the next

level. “We work with our customers to

understand their business, their pain points,

and where they want to be in the future,”

says Jan. Being knowledgeable in the

industry allows the company to understand

each client's specific situation and allowing

it to be flexible to design the tools they need

to be successful. The goal is to add value

and transparency to all levels of the

organization.

Metrendalytics aims to improve the “life of

the scientist in the laboratory” by providing

tools to leverage already existing

information. It helps mid-level managers

drive improvement gains through

automated capture of metrics and trends. It

also provides senior-level executives up to

the minute visibility to their entire portfolio

to understand the current status of their

projects and where action is needed to keep

programs on track. By being more efficient

with information, the company helps all

levels of the organization perform better to

help take time and cost out of the drug

development process.

Current Crisis and Future Opportunities

Metrendalytics has always been at the

forefront when it comes to how it uses the

information to improve business results. It

will continue to do so in the future. The

recent Covid-19 pandemic has accelerated

the adoption of cloud-based and remotely

accessed information systems. The

company will build on its past success in

this area to develop new and expanded


capabilities to meet the full-service needs of its customers.

The company asserts “Our low cost, rapid development

model also makes replacing some of the disconnected and

more expensive “point solution” systems possible.”

Metrendalytics continues to build a network of experienced,

results-oriented subject matter experts in the laboratory,

drug metabolism, and chemistry manufacturing and

controls. This expanded knowledge base provides access to

new markets and the opportunity to leverage its technology

to benefit these areas.

Socially Responsible

Metrendalytics is active in Corporate Social Responsibility

including philanthropy, environment conservation, diversity

and labor practices, and volunteerism. As a company,

Metrendalytics is diverse and designated as a femaleowned,

minority business and some of its partners are also

minority-based.

It has donated time and resources to start-up groups and

technology companies that share the same passion for data

and using that data to build the next-generation laboratory

or improving upon existing technology to help the day-today

work life of the scientist.

On Drug Development Challenges

Drug development is a long and costly process typically

requiring approximately 10 years and hundreds of millions

of dollars. By developing solutions that reduce this time and

cost, Metrendalytics not only saves money for customers

but also helps get products to market faster. As a result, the

public has access to potentially life-saving medications

sooner. This in turn provides a revenue stream for the

pharma company to reinvest in future drug development.

For CROs, where the name of the game is efficiency and

value, here again, Metrendalytics helps to improve both of

these. The more efficient the resources are in a CRO, the

more projects can be completed, which accelerates drug

development as noted above. It also means better

profitability and stability for the CRO.

For both CROs and pharma biotech companies, the time

saved translates to more focus on the actual work of drug

development instead of time wasted collecting and

managing information. That time saved can then channelled

into value-added activities like quality control, assessment

and impact analysis or actions or innovations to improve

the outcome.

Testimonials from Clients

“Jan and her team at Metrendalytics collaborated with our

team at Alturas Analytics to create a total customized

information management system that organizes and

manages client information, data and resource

management. The system has improved productivity,

efficiency and compliance in our bioanalytical CRO. Thank

you Metrendalytics!”

-Shane Needham, Co-Founder and Chief Scientific

Officer at Alturas Analytics, Inc.

“Immunologix Labs is accelerating our bioanalytical

service delivery to the technology forefront with the

Metrendalytics initiative. The platform will be our primary

driver for industry-leading efficiency, organization and

client experience. It will provide the architecture to

seamlessly ensure consistent, high-quality, on-time

performance for our clients. We are very enthusiastic about

our partnership with Jahanara (Jan) Miotto and the team at

Metrendalytics"

-Michael Anderson, President and Chief Executive

Officer at Immunologix Laboratories

“We are on an exciting journey with Metrendalytics in

moving from a paper heavy lab to a paper-lite lab to a

paperless lab, which will enhance the efficiency of the

entire laboratory process, leading to a dramatic overall

cost reduction in operations and a better way to work for

everyone. Many thanks to Metrendalytics in bringing our

vision into reality”

-Luca C Matassa, VP and Head of Bioanalytical at QPS

Laboratoriese operational data for real-time use”



Triox Na

Pioneers in point of care programmable medicine! presenting th

n an interview with Insights Success, Triox Nano's

Imanagement describes its impeccable journey to

become the first biotech company to develop a

modular programmed drug delivery platform. The

company's revolutionary technology, termed S.M.A.R.T, an

acronym for Stimuli Multi Adjusted Responsive

Technology, or simply put “Programmable medicine” is

based on combinations of DNA coding, DNA molecular

machines and mesoporous nanoparticles. SMART offers the

potential to add programming to almost any approved

medicine that may in turn increase its efficacy

exponentially.

Prominent opinion leaders and investors had been funding

TrioxNano's development to date including the European

commission through the prestigious H2020 Horizon

program. Competing with over 1500 companies

TrioxNano's technology won a non diluting grant of

roughly $2.5 million USD. TrioxNano's all inclusive patents

are granted around the world . Many believe this

breakthrough technology may lead the way to the next

healthcare revolution!

To create S.M.A.R.T Triox Nano had to first invent the

modular hardware that will allow incorporation of many

different medications, the software language which is based

on DNA coding and the actual codes that will control the

nano particle. The technology is expected to create a

paradigm shift and highly impact human lives around

the globe, transforming medicine from its current primitive

analog state to a programmable digital modern era.

S.M.A.R.T creates a vast field of programmable

nanoparticles that can deliver their payload to target tissues

based on the software code that is uploaded to them. The

final commercialized product is expected to be supplied

with a list of common software codes. The treating

physician will decide which codes to use and will easily

upload them to the modular nanoparticle that incorporates

the relevant medication. The doctor will have the option to

upload a mixture of several codes into the same treatment

based on the patient's clinical and pathologic profile.

Under the supervision of Joseph Farfara, Triox Nano's

CEO, the company has progressed robustly in the last 3

years, broadening the type of medications that can be

loaded into the platform, improving the capping

characteristics and securing its IP with patents granted

around the world.

Below are the highlights of the interview:

Can you explain to our readers what so exciting about

Triox Nano work?

Joseph Farfara, Triox Nano's CEO “By the year 2020,

thousands of APIs (Active Pharmaceutical Ingredients) had

been developed to treat different diseases, yet not even one

efficient modular technology was developed to deliver them

accurately to their target! The most efficient way to do this

is use programming abilities so that each API can have tens

of programs to direct it to different targets upon request. If

you compare this to the car industry its like everyone has

been developing thousands of types of engines without

finding a way to connect them to the wheels yet. Current

delivery methods, such as Injections or tablets deliver only

a small percentage of their original doses to the tissues

requiring treatment, and instead, most of the dose arrives to

healthy tissue causing severe toxicity.

Examples for our programing abilities include the TXN770

family of nanoparticles intended for the treatment of TNBC

(Triple Negative Breast Cancer). TXN770 combines

between a modular unit loaded with the chemotherapy

doxorubicin, that is already approved for the treatment of

TNBC and the ability to be programmed by a combination

of different software codes that control its release according

to common traits found in the patient's specific tumor such

as high levels of Magnesium and high levels of ATP. Other

programing options we are developing include high levels


no

e next healthcare revolution!

of PD1, PARP and Nucleolin found to be high in subgroups

of TNBC patients. This allows us to use the same modular

particle that includes Doxorubicin and program it to react to

different cancer traits. In parallel we have created other

modular particle loaded with the chemotherapies

Mitoxantrone and Docetaxel (that is approved already for

TNBC) that can use the same software codes described

above (Mg, ATP, PD1, PARP, Nucleolin).

We are focusing on TNBC Triple Negative Breast Cancer to

prove our technology's benefits but expect it to be relevant

for many other indications. We offer specific licenses to

the use of our S.M.A.R.T platform loaded with the

client's APIs (active pharmaceutical ingredient). This is

relevant for many types of companies, those who have a

medication that is effective but proven to be too toxic to be

used, or for medications that require high doses to be

effective, or in cases patent cliff issues have to be avoided.

Our standard license agreements includes milestone

payments and royalties fees, we offer our services for a fee

to develop the asset until completion of the of In Vitro

phase, expecting the companies to complete the In Vivo Tox

and clinical trials.

What led to the inception of Triox Nano?

Answer Dr. Roy Farfara CTO and founder of

TrioxNano

The inception of TrioxNano was at 2 AM after a long

operation of a young kidney cancer patient. Our department

was regularly accepting patients that other surgeons had

given up on operating them due to the technical difficulties.

We had the best techniques and technologies in Israel at the

time (biologic glues, mannitol, hypothermia) we were

taking out carefully tumor after tumor in the renal. We

finished the surgery exhausted though we knew we did the

best that can possibly be done. The patient kidney was not

resected, we managed to take out all tumors and substantial

bleeding avoided. Yet we understood that the patient ended

Roy Farfara, MD

Founder & CTO


“Triox Nano’s technology offers a paradigm shift that will highly impact

human lives, transforming medicine from an analog state to an

exciting programmable digital modern era”

up having less than %20 of the original kidney parenchyma

meaning he would most probably need dialysis in the near

future. My grandfather Simon Farfara RIP who was an

artisan taught me when I was a child that "The first step in

every challenge is to find the best tools to complete it".

Understanding that it is not possible that in the year 2013

we are trying to resect micron (one millionths of a meter)

size cancer cells with centimeter size knifes while on the

other hand treating with chemotherapy that is not specific

enough thus causing substantial side effects. Being aware of

the limitation of surgery (trying to resect micro meter size

cancer cells with inch size knifes) and the limitations of non

specific chemotherapies causing substantial toxicity made

me understand at that moment that we are totally not using

the right tools to achieve this goal, and set me out on this

journey”

Describe Triox Nano and its cutting-edge technology.

Answer Dr. Ehud Saas head of biologic programming

Interestingly computers have been incorporated into

everyaspect of our lives except medicine. TrioxNano has

developed and patented a programmable nano delivery

platform that can carry different medications, including

chemotherapies, to their target tissue. The technology uses

nanoparticles based on DNA machinery. These amazing

machines are made from single-stranded DNA and RNA

and allow us to program a modular particle with almost

infinite possibilities. Once completed, the technology will

enable the treating physician to upload the relevant DNA

module per individual patient and precise the administered

treatment based on his specific cancer traits. It is estimated

that more than 1000 approved medication can be delivered

by this programmable system and at least 500 unique

programmed modules can be uploaded to them. This adds

up to about half a million different options of unique

treatments (in the case that only one code is uploaded per

particle), in the case a combination of three codes is loaded

and estimated 125 billion treatment options are created.

As a leading pharma and biotech solution providers, what

contribution has been made by you?

Answer by Dr. Ofer Nusbaum head of chemistry biology

interface.

TrioxNano is trying to create a paradigm shift in the way

we treat disease. Programming is urgently need to enhance

the treatment of patients. In the case of Cancer as an

example, cancer cells develop different mutations in

different organs of the same patient. On the other hand

different cancer type share common pathways. For example

the PD1 pathway is relevant for a small percentage of

TNBC patients and larger percentage in many other cancer

types, many are being treated with PD1 inhibitors. This

translate into a need for modular programmed platform that

can relate to common traits in different tumors and different

mutation in the same patient. We believe we will be able to

offer the world the first modular programmable nano

delivery platform where the physician will be able to

program the medicine he gives his patient, he will choose

from a list of software codes that we will offer commercialy

and upload it to an armantarium of medication he can

choose from. Later on we plan to offer specific

programming to less common cases that require specific

softwares. Of note is that all the different chemotherapies

are packed in the same modular nanoparticle.

Describe in brief about the work culture and the values

that drive Triox Nano.

Joseph Farfara, Triox Nano's CEO

TrioxNano is driven by a team of highly intelligent hard

working open minded scientist. All our staff have hands on

experience of years in the industry. We are roughly divided

to chemists and biologists that are integrators able to bridge

the gap between these two worlds. As an Israeli company

we try to think out the box and “cut to chase” as much as

possible basing our decision on sound science.

What are the future aspirations of Triox Nano? What

strategies are you undertaking to achieve those goals?


TrioxNano

TrioxNano aspires to be the next Microsoft and IBM, on

one hand creating "the operating system for computerized

drug delivery" and on the other developing the hardware

required to run the operation system and the code. We want

to revolutionize the way patients are treated! To achieve this


goal our strategies include a hybrid business model where

we develop our own drug candidate TXN770 (as a proof of

concept) for the treatment of TNBC but are actively

persuing to cooperate with others to incorporate their APIs

(Active Pharmaceutical Ingredients) into our modular

computerized platform.

How are you solving your customers' complex drug

discovery challenges?


TrioxNano

By incorporating their APIs into TrioxNano's S.M.A.R.T

platform, our partners may be able to increase efficacy

while using smaller doses, creating decreased toxicity, new

IP and an exponential increase in value. This cooperation

will importantly benefit humanity as thousands of

medications can be improved which translate into

improving human lifes!

What is your idea of Corporate Social Responsibility?

Joseph Farfara, Triox Nano's CEO

The hebrew saying "KOL HAMEZIL NEFESH ACHAT

KEILU HEZIL OLAM U MELO'O," meaning he who

saves one life is considered to save the world entire.

www.Smartriox.com

Joseph@TrioxNano.com

“It is estimated that more than 1000 approved medication can be delivered by this

programmable system and at least 500 unique programs can be uploaded to them.

This adds up to about half a million different options of unique treatments (in the

case that only one code is uploaded per particle), in the case a combination of three

codes is loaded and estimated 125 billion treatment options are created."


The 10 Successful Magnetic Leaders Revamping The Healthcare

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?